2-[18F]Fluoro-2-Deoxyglucose Positron-Emission Tomography in Staging, Response Evaluation, and Treatment Planning of Lymphomas

Seminars in Radiation Oncology

Volumn 17, Issue 3, 2007, Pages 190-197

  Specht, Lena ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; PREDNISONE; VINCRISTINE;

ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; HODGKIN DISEASE; HUMAN; INTERMETHOD COMPARISON; LUNG CANCER; LYMPHOMA; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT PLANNING; TREATMENT RESPONSE;

FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; LYMPHOMA; LYMPHOMA, NON-HODGKIN; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEOPLASM, RESIDUAL; PATIENT CARE PLANNING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RADIOTHERAPY, CONFORMAL; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 34250698039     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semradonc.2007.02.005     Document Type: Article

References (128)

1. Price P.M., and Jones T. The role of PET scanning in radiotherapy. Br J Radiol 28 suppl (2005) 2-4
2. Paul R. Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma. J Nucl Med 28 (1987) 288-292
3. Hutchings M., Loft A., and Hansen M. Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake. Hematol Oncol 24 (2006) 146-150
4. Lapela M., Leskinen S., and Minn H.R. Increased glucose metabolism in untreated non-Hodgkin's lymphoma: A study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood 86 (1995) 3522-3527
5. Leskinen-Kallio S., Ruotsalainen U., and Nagren K. Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: A PET study. J Nucl Med 32 (1991) 1211-1218
6. Newman J.S., Francis I.R., and Kaminski M.S. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: Correlation with CT. Radiology 190 (1994) 111-116
7. Okada J., Yoshikawa K., and Imazeki K. The use of FDG-PET in the detection and management of malignant lymphoma: Correlation of uptake with prognosis. J Nucl Med 32 (1991) 686-691
8. Okada J., Yoshikawa K., and Itami M. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: A comparison with proliferative activity. J Nucl Med 33 (1992) 325-329
9. Rodriguez M., Rehn S., and Ahlstrom H. Predicting malignancy grade with PET in non-Hodgkin's lymphoma. J Nucl Med 36 (1995) 1790-1796
10. Schoder H., Noy A., and Gonen M. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol 23 (2005) 4643-4651
11. Ambrosini V., Rubello D., and Castellucci P. Diagnostic role of 18F-FDG pet in gastric MALT lymphoma. Nucl Med Rev Cent East Eur 9 (2006) 37-40
12. Jerusalem G., Beguin Y., and Najjar F. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Ann Oncol 12 (2001) 825-830
13. Najjar F., Hustinx R., and Jerusalem G. Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphomas (NHL). Cancer Biother Radiopharm 16 (2001) 297-304
14. Buchmann I., Moog F., and Schirrmeister H. Positron emission tomography for detection and staging of malignant lymphoma. Recent Results Cancer Res 156 (2000) 78-89
15. Buchmann I., Reinhardt M., and Elsner K. 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer 91 (2001) 889-899
16. Burton C., Ell P., and Linch D. The role of PET imaging in lymphoma. Br J Haematol 126 (2004) 772-784
17. Hutchings M., Eigtved A.I., and Specht L. FDG-PET in the clinical management of Hodgkin lymphoma. Crit Rev Oncol Hematol 52 (2004) 19-32
18. Hutchings M., Loft A., and Hansen M. Positron emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma. Haematologica 91 (2006) 482-489
19. Jerusalem G., Beguin Y., and Fassotte M.F. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Haematologica 86 (2001) 266-273
20. Jerusalem G., Hustinx R., and Beguin Y. Positron emission tomography imaging for lymphoma. Curr Opin Oncol 17 (2005) 441-445
21. Menzel C., Dobert N., and Mitrou P. Positron emission tomography for the staging of Hodgkin's lymphoma-Increasing the body of evidence in favor of the method. Acta Oncol 41 (2002) 430-436
22. Barrington S.F., and O'Doherty M.J. Limitations of PET for imaging lymphoma. Eur J Nucl Med Mol Imaging 30 suppl 1 (2003) S117-S127
23. Elstrom R., Guan L., and Baker G. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 101 (2003) 3875-3876
24. Hoffmann M., Kletter K., and Becherer A. 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma. Oncology 64 (2003) 336-340
25. Hoffmann M., Chott A., and Puspok A. 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) does not visualize follicular lymphoma of the duodenum. Ann Hematol 83 (2004) 276-278
26. Jerusalem G.H., and Beguin Y.P. Positron emission tomography in non-Hodgkin's lymphoma (NHL): Relationship between tracer uptake and pathological findings, including preliminary experience in the staging of low-grade NHL. Clin Lymphoma 3 (2002) 56-61
27. Pakos E.E., Fotopoulos A.D., and Ioannidis J.P. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: A meta-analysis. J Nucl Med 46 (2005) 958-963
28. Wohrer S., Jaeger U., and Kletter K. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading. Ann Oncol 17 (2006) 780-784
29. Specht L. Staging systems and staging investigations at presentation. In: Magrath I. (Ed). The Lymphoid Neoplasms (2006), Hodder Arnold, London
30. Bendini M., Zuiani C., and Bazzocchi M. Magnetic resonance imaging and 67Ga scan versus computed tomography in the staging and in the monitoring of mediastinal malignant lymphoma: A prospective pilot study. MAGMA 4 (1996) 213-224
31. Tomura N., Hirano H., and Sashi R. Comparison of MR imaging and CT in discriminating tumor infiltration of bone and bone marrow in the skull base. Comput Med Imaging Graph 22 (1998) 41-51
32. Wyttenbach R., Vock P., and Tschappeler H. Cross-sectional imaging with CT and/or MRI of pediatric chest tumors. Eur Radiol 8 (1998) 1040-1046
33. Front D., and Israel O. Present state and future role of gallium-67 scintigraphy in lymphoma. J Nucl Med 37 (1996) 530-532
34. Kostakoglu L., Leonard J.P., and Kuji I. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer 94 (2002) 879-888
35. Wirth A., Seymour J.F., and Hicks R.J. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med 112 (2002) 262-268
36. Even-Sapir E., and Israel O. Gallium-67 scintigraphy: A cornerstone in functional imaging of lymphoma. Eur J Nucl Med Mol Imaging 30 suppl 1 (2003) S65-S81
37. Friedberg J.W., Fischman A., and Neuberg D. FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: A blinded comparison. Leuk Lymphoma 45 (2004) 85-92
38. Kostakoglu L., Leonard J.P., and Coleman M. The role of FDG-PET imaging in the management of lymphoma. Clin Adv Hematol Oncol 2 (2004) 115-121
39. Van Den Bossche B., Lambert B., and De Winter F. 18FDG PET versus high-dose 67Ga scintigraphy for restaging and treatment follow-up of lymphoma patients. Nucl Med Commun 23 (2002) 1079-1083
40. Yamamoto F., Tsukamoto E., and Nakada K. 18F-FDG PET is superior to 67Ga SPECT in the staging of non-Hodgkin's lymphoma. Ann Nucl Med 18 (2004) 519-526
41. Zijlstra J.M., Hoekstra O.S., and Raijmakers P.G. 18FDG positron emission tomography versus 67Ga scintigraphy as prognostic test during chemotherapy for non-Hodgkin's lymphoma. Br J Haematol 123 (2003) 454-462
42. Bangerter M., Moog F., and Buchmann I. Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. Ann Oncol 9 (1998) 1117-1122
43. Carr R., Barrington S.F., and Madan B. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 91 (1998) 3340-3346
44. Delbeke D., Martin W.H., and Morgan D.S. 2-deoxy-2-[F-18]fluoro-D-glucose imaging with positron emission tomography for initial staging of Hodgkin's disease and lymphoma. Mol Imaging Biol 4 (2002) 105-114
45. Hoh C.K., Glaspy J., and Rosen P. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med 38 (1997) 343-348
46. Hueltenschmidt B., Sautter-Bihl M.L., and Lang O. Whole body positron emission tomography in the treatment of Hodgkin disease. Cancer 91 (2001) 302-310
47. Isasi C.R., Lu P., and Blaufox M.D. A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer 104 (2005) 1066-1074
48. Jerusalem G., Warland V., and Najjar F. Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Nucl Med Commun 20 (1999) 13-20
49. Moog F., Bangerter M., and Diederichs C.G. Lymphoma: Role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology 203 (1997) 795-800
50. Moog F., Bangerter M., and Diederichs C.G. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 206 (1998) 475-481
51. Moog F., Kotzerke J., and Reske S.N. FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma. J Nucl Med 40 (1999) 1407-1413
52. Munker R., Glass J., and Griffeth L.K. Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's disease. Ann Oncol 15 (2004) 1699-1704
53. Partridge S., Timothy A., and O'Doherty M.J. 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: Influence on patient management in a single institution. Ann Oncol 11 (2000) 1273-1279
54. Rini J.N., Leonidas J.C., and Tomas M.B. 18F-FDG PET versus CT for evaluating the spleen during initial staging of lymphoma. J Nucl Med 44 (2003) 1072-1074
55. Sasaki M., Kuwabara Y., and Koga H. Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma. Ann Nucl Med 16 (2002) 337-345
56. Schiepers C., Filmont J.E., and Czernin J. PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 30 suppl 1 (2003) S82-S88
57. Schoder H., Meta J., and Yap C. Effect of whole-body (18)F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma. J Nucl Med 42 (2001) 1139-1143
58. Shah N., Hoskin P., and McMillan A. The impact of FDG positron emission tomography imaging on the management of lymphomas. Br J Radiol 73 (2000) 482-487
59. Stumpe K.D., Urbinelli M., and Steinert H.C. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: Effectiveness and comparison with computed tomography. Eur J Nucl Med 25 (1998) 721-728
60. Weihrauch M.R., Re D., and Bischoff S. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease. Ann Hematol 81 (2002) 20-25
61. Beal K.P., Yeung H.W., and Yahalom J. FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: A report of 42 cases. Ann Oncol 16 (2005) 473-480
62. Hadithi M., Mallant M., and Oudejans J. 18F-FDG PET versus CT for the detection of enteropathy-associated T-cell lymphoma in refractory celiac disease. J Nucl Med 47 (2006) 1622-1627
63. Hoffmann M., Vogelsang H., and Kletter K. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) for assessment of enteropathy-type T cell lymphoma. Gut 52 (2003) 347-351
64. Roe R.H., Finger P.T., and Kurli M. Whole-body positron emission tomography/computed tomography imaging and staging of orbital lymphoma. Ophthalmology 113 (2006) 1854-1858
65. Shapiro M., Yun M., and Junkins-Hopkins J.M. Assessment of tumor burden and treatment response by 18F-fluorodeoxyglucose injection and positron emission tomography in patients with cutaneous T- and B-cell lymphomas. J Am Acad Dermatol 47 (2002) 623-628
66. Cheson B.D., Horning S.J., Coiffier B., and NCI Sponsored International Working Group. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 17 (1999) 1244-1253
67. Lister T.A., Crowther D., and Sutcliffe S.B. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 7 (1989) 1630-1636
68. Bangerter M., Kotzerke J., and Griesshammer M. Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest. Acta Oncol 38 (1999) 799-804
69. Becherer A., Jaeger U., and Szabo M. Prognostic value of FDG-PET in malignant lymphoma. Q J Nucl Med 47 (2003) 14-21
70. Cremerius U., Fabry U., and Neuerburg J. Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun 19 (1998) 1055-1063
71. de Wit M., Bumann D., and Beyer W. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann Oncol 8 suppl 1 (1997) 57-60
72. de Wit M., Bohuslavizki K.H., and Buchert R. 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol 12 (2001) 29-37
73. Dittmann H., Sokler M., and Kollmannsberger C. Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma. Oncol Rep 8 (2001) 1393-1399
74. Freudenberg L.S., Antoch G., and Schutt P. FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging 31 (2004) 325-329
75. Guay C., Lepine M., and Verreault J. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation. J Nucl Med 44 (2003) 1225-1231
76. Jerusalem G., Beguin Y., and Fassotte M.F. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 94 (1999) 429-433
77. Juweid M.E., Wiseman G.A., and Vose J.M. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 23 (2005) 4652-4661
78. Kazama T., Faria S.C., and Varavithya V. FDG PET in the evaluation of treatment for lymphoma: Clinical usefulness and pitfalls. Radiographics 25 (2005) 191-207
79. Lang O., Bihl H., and Hultenschmidt B. Clinical relevance of positron emission tomography (PET) in treatment control and relapse of Hodgkin's disease. Strahlenther Onkol 177 (2001) 138-144
80. Lavely W.C., Delbeke D., and Greer J.P. FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy. Int J Radiat Oncol Biol Phys 57 (2003) 307-315
81. Maisey N.R., Hill M.E., and Webb A. Are 18fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses?. Eur J Cancer 36 (2000) 200-206
82. Mikhaeel N.G., Timothy A.R., and Hain S.F. 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. Ann Oncol 11 suppl 1 (2000) 147-150
83. Naumann R., Vaic A., and Beuthien-Baumann B. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol 115 (2001) 793-800
84. Panizo C., Perez-Salazar M., and Bendandi M. Positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual Hodgkin's disease mediastinal masses. Leuk Lymphoma 45 (2004) 1829-1833
85. Rahmouni A., Luciani A., and Itti E. Quantitative CT analysis for assessing response in lymphoma (Cheson's criteria). Cancer Imaging 5 (2005) S102-S106
86. Reinhardt M.J., Herkel C., and Altehoefer C. Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: When do we really need FDG-PET?. Ann Oncol 16 (2005) 1524-1529
87. Reske S.N. PET and restaging of malignant lymphoma including residual masses and relapse. Eur J Nucl Med Mol Imaging 30 suppl 1 (2003) S89-S96
88. Rigacci L., Castagnoli A., and Dini C. 18FDG-positron emission tomography in post treatment evaluation of residual mass in Hodgkin's lymphoma: Long-term results. Oncol Rep 14 (2005) 1209-1214
89. Spaepen K., Stroobants S., and Dupont P. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?. Br J Haematol 115 (2001) 272-278
90. Spaepen K., Stroobants S., and Dupont P. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: Is [18F]FDG-PET a valid alternative to conventional diagnostic methods?. J Clin Oncol 19 (2001) 414-419
91. Weihrauch M.R., Re D., and Scheidhauer K. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 98 (2001) 2930-2934
92. Zijlstra J.M., Lindauer-van der Werf G., and Hoekstra O.S. 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: A systematic review. Haematologica 91 (2006) 522-529
93. Zinzani P.L., Magagnoli M., and Chierichetti F. The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol 10 (1999) 1181-1184
94. Zinzani P.L., Chierichetti F., and Zompatori M. Advantages of positron emission tomography (PET) with respect to computed tomography in the follow-up of lymphoma patients with abdominal presentation. Leuk Lymphoma 43 (2002) 1239-1243
95. Diehl V., Specht L., and Pfistner B. Response criteria in malignant lymphomas revisited-A proposal of the International Harmonization Project of the Competence Network of Malignant Lymphoma. Hematology (EHA Educ Program) 2 (2006) 151-153
96. Cheson B.D., Pfistner B., and Juweid M.E. Revised response criteria for malignant lymphoma. J Clin Oncol 25 (2007) 579-586
97. Juweid M.E., Stroobants S., and Mottaghy F.M. Use of positron emission tomography (PET) for response assessment of lymphoma: Consensus of the Imaging Subcommittee of the International Harmonization Project in Lymphoma. J Clin Oncol 25 (2007) 571-578
98. Findlay M., Young H., and Cunningham D. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: Correlation with tumor response to fluorouracil. J Clin Oncol 14 (1996) 700-708
99. Jansson T., Westlin J.E., and Ahlstrom H. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: A method for early therapy evaluation?. J Clin Oncol 13 (1995) 1470-1477
100. Wahl R.L., Zasadny K., and Helvie M. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation. J Clin Oncol 11 (1993) 2101-2111
101. Romer W., Hanauske A.R., and Ziegler S. Positron emission tomography in non-Hodgkin's lymphoma: Assessment of chemotherapy with fluorodeoxyglucose. Blood 91 (1998) 4464-4471
102. Gallamini A., Rigacci L., and Merli F. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 91 (2006) 475-481
103. Haioun C., Itti E., and Rahmouni A. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: An early prognostic tool for predicting patient outcome. Blood 106 (2005) 1376-1381
104. Hutchings M., Mikhaeel N.G., and Fields P.A. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 16 (2005) 1160-1168
105. Hutchings M., Loft A., and Hansen M. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107 (2006) 52-59
106. Jerusalem G., Beguin Y., and Fassotte M.F. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica 85 (2000) 613-618
107. Kostakoglu L., Coleman M., and Leonard J.P. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 43 (2002) 1018-1027
108. Mikhaeel N.G., Hutchings M., and Fields P.A. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 16 (2005) 1514-1523
109. Spaepen K., Stroobants S., and Dupont P. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 13 (2002) 1356-1363
110. Zinzani P.L., Tani M., and Fanti S. Early positron emission tomography (PET) restaging: A predictive final response in Hodgkin's disease patients. Ann Oncol 17 (2006) 1296-1300
111. Girinsky T., Pichenot C., and Beaudre A. Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin's disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes?. Int J Radiat Oncol Biol Phys 64 (2006) 218-226
112. Specht L., Gray R.G., Clarke M.J., and International Hodgkin's Disease Collaborative Group. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: A meta-analysis of 23 randomized trials involving 3,888 patients. J Clin Oncol 16 (1998) 830-843
113. Yahalom J. Transformation in the use of radiation therapy of Hodgkin lymphoma: New concepts and indications lead to modern field design and are assisted by PET imaging and intensity modulated radiation therapy (IMRT). Eur J Haematol 66 suppl (2005) 90-97
114. Berthelsen AK, Dobbs J, Kjellén E: What's new in target volume definitions for radiologists in ICRU Report 71? How can the ICRU volume definitions be integrated in clinical practice? Cancer Imaging (in press)
115. Daisne J.F., Duprez T., and Weynand B. Tumor volume in pharyngolaryngeal squamous cell carcinoma: Comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology 233 (2004) 93-100
116. Gregoire V. Is there any future in radiotherapy planning without the use of PET: Unraveling the myth. Radiother Oncol 73 (2004) 261-263
117. Jarritt P.H., Carson K.J., and Hounsell A.R. The role of PET/CT scanning in radiotherapy planning. Br J Radiol 79 (2006) S27-S35 (spec no 1)
118. Jarritt P.H., Hounsell A.R., and Carson K.J. Use of combined PET/CT images for radiotherapy planning: Initial experiences in lung cancer. Br J Radiol 28 suppl (2005) 33-40
119. Girinsky T., van der Maazen R., and Specht L. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: Concepts and guidelines. Radiother Oncol 79 (2006) 270-277
120. van Baardwijk A., Baumert B.G., and Bosmans G. The current status of FDG-PET in tumour volume definition in radiotherapy treatment planning. Cancer Treat Rev 32 (2006) 245-260
121. Dizendorf E.V., Baumert B.G., and von Schulthess G.K. Impact of whole-body 18F-FDG PET on staging and managing patients for radiation therapy. J Nucl Med 44 (2003) 24-29
122. Lee Y.K., Cook G., and Flower M.A. Addition of 18F-FDG-PET scans to radiotherapy planning of thoracic lymphoma. Radiother Oncol 73 (2004) 277-283
123. Asakura H., Togami T., and Mitani M. Usefulness of FDG-PET imaging for the radiotherapy treatment planning of pyothorax-associated lymphoma. Ann Nucl Med 19 (2005) 725-728
124. Krasin M.J., Hudson M.M., and Kaste S.C. Positron emission tomography in pediatric radiation oncology: Integration in the treatment-planning process. Pediatr Radiol 34 (2004) 214-221
125. Brianzoni E., Rossi G., and Ancidei S. Radiotherapy planning: PET/CT scanner performances in the definition of gross tumour volume and clinical target volume. Eur J Nucl Med Mol Imaging 32 (2005) 1392-1399
126. Hutchings E., Berthelsen G., and Loft S. Clinical impact of FDG-PET/CT in the planning of radiotherapy for early stage Hodgkin lymphoma. Eur J Haematol 78 (2007) 206-212
127. Saleem A. Potential of PET in oncology and radiotherapy. Br J Radiol Suppl 28 (2005) 6-16
128. West C.M.L., and Charnley N. The potential of PET to increase understanding of the biological basis of tumour and normal tissue response to radiotherapy. Br J Radiol Suppl 28 (2005) 50-54